Chronic pain can affect a person’s life in a myriad of ways. Asal Shirazi BEM, Founder of the Autoimmune Support & Awareness Foundation (ASA Foundation), talks us through some of the conditions associated with chronic pain and the advancements in pain management.
A groundbreaking study demonstrates the efficacy of administering a previously injection-only medication for osteoporosis through an innovative robotic pill.
AI and Anti-aging research: According to a study, AI algorithms (AI) has led to the discovery of three drugs that have the potential to delay the effects of aging.
Monica Racoviță, Senior Researcher at The Health Policy Partnership, argues that opioid dependence is a pressing issue, yet treatment for it is still out of reach for many.
In a surprising turn of events, Prince Harry's public endorsement of the transformative power of psychedelic therapy has triggered a psychedelic resurgence in the UK.
The effect of the anti-ageing drug rapamycin differs in male and female fruit flies, find researchers, who seek to understand how sex influences the development of age-related disease.
Paul Sommerfeld, Executive Trustee, TB Alert and Chair, TB Europe Coalition, walks us through tackling tuberculosis. We hear that while there are continuing problems, there are finally grounds for optimism.
Dr Gerard Sinovich, Lead Pain Specialist, provides an in-depth commentary on behalf of Cantourage Clinic concerning what we need to know about opioids and opioid dependence.
Efforts to prevent or treat Alzheimer’s Disease (AD) by targeting Amyloid beta (Aβ) assemblies should be continued, but the strategies should be altered dramatically.
Dr Zisis Kozlakidis directs our thoughts towards the molecular aspects of global Infection Prevention and Control, in this the second of a special two-part series.
In this interview, Abbas Kanani, MRPharmS, Superintendent Pharmacist at Chemist Click, tells us about amyloidosis, a group of rare diseases in which abnormal proteins deposit as amyloid in tissues and organs.
David Nutt FMedSci, Chair Drug Science and PAREA, Prof of Neuropsychopharmacology at Imperial College London, explains why Europe needs to catch up with psychedelic research.
